Possible antipsychotic effect of fluvoxamine.
Goldman
Sara
S
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016666:Fluvoxamine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use
D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D015283:Citalopram; D018967:Risperidone; D016666:Fluvoxamine